First Tracks Biotherapeutics stock surges 20% on celiac trial data

5 ETFs I'm Buying and Holding Through the Next Bear Market and Beyond

NASDAQ · Markets 14m ago

AxoGen stock initiated at Buy by BofA on growth outlook

Investing.com · News 14m ago

BofA raises Helmerich & Payne stock price target to $46 on tech edge

Investing.com · News 14m ago

BofA cuts Insmed stock price target on valuation concerns

Investing.com · News 14m ago

BofA raises Gilead Sciences stock price target on growth outlook

Investing.com · News 14m ago

BofA cuts Vertex stock price target to $667 on CF franchise outlook

Investing.com · News 14m ago

4 Years Into the Bull Market

Investing.com · Overview 15m ago

UBS sees scope for milder UK budget as markets focus on fiscal credibility

Investing.com · News 15m ago

UBS sees scope for milder UK budget as markets focus on fiscal credibility

Investing.com · Investing_news 15m ago

InvestingPro’s fair value warned CAVA was overvalued before 47% drop

Investing.com · News 17m ago